Detecting minimal residual disease in multiple myeloma using advanced genetic techniques
Clinical Utility of Ultrasensitive Chromosomal Aberrations Detection (UCAD) for Detecting Minimal Residual Disease (MRD) and Monitoring Clonal Evolution by Low-Pass Whole Genome Sequencing in Multiple Myeloma
This study is testing a new genetic method to see if it can better detect leftover cancer cells in people with multiple myeloma after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China Academic / other |
| Locations | 1 site (Tianjin, Tianjin) |
| Trial ID | NCT06302699 on ClinicalTrials.gov |
What this trial studies
This study focuses on detecting minimal residual disease (MRD) in patients with multiple myeloma by utilizing ultrasensitive chromosomal aberrations detection through low-pass whole genome sequencing. It aims to evaluate the correlation between MRD identified by flow cytometry and the genetic variations detected via this advanced sequencing method. Nearly 200 patient samples will be analyzed to monitor clonal evolution and assess the effectiveness of this approach in providing sensitive and accurate MRD detection. Follow-up samples will also be collected to ensure comprehensive monitoring over time.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with multiple myeloma who have available baseline and sequential next-generation flow-MRD data.
Not a fit: Patients without baseline and sequential next-generation flow-MRD data may not receive any benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate monitoring of minimal residual disease in multiple myeloma, potentially improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using genetic sequencing techniques for monitoring minimal residual disease, indicating that this approach has potential based on prior research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects diagnosed with MM. * With available baseline and sequential next-generation flow-MRD data. Exclusion Criteria: * Subjects without baseline and sequential next-generation flow-MRD data.
Where this trial is running
Tianjin, Tianjin
- InsituteHBDH — Tianjin, Tianjin, China (Recruiting)
Study contacts
- Study coordinator: Gang An, PhD&MD
- Email: angang@ihcams.ac.cn
- Phone: 008613502181109
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.